EC Approves Bristol-Myers Squibb's Empliciti Treatment for Certain Myeloma Patients
August 27 2019 - 5:53PM
Dow Jones News
By Stephen Nakrosis
Bristol-Myers Squibb Co. (BMY) on Tuesday said the European
Commission has approved the use of Empliciti, or elotuzumab, in
combination for some patients with multiple myeloma.
The drugmaker said the approval was for Empliciti Plus
Pomalidomide and Low-Dose Dexamethasone, or EPd, to treat patients
with relapsed and refractory multiple myeloma.
According to the company, the "median progression-free survival
and overall response rate doubled among patients receiving EPd
compared to pomalidomide and low-dose dexamethasone alone."
This is the second Empliciti-based combination approved in
Europe for those patients, the company said.
Bristol-Myers Squibb said the U.S. Food and Drug Administration
approved this combination to treat adult patients with multiple
myeloma who have received at least two prior therapies in November
of last year.
Bristol-Myers Squibb is co-developing Empliciti with AbbVie Inc.
(ABBV). Bristol-Myers Squibb said it is responsible for commercial
activities.
--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
August 27, 2019 17:38 ET (21:38 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Apr 2023 to Apr 2024
